Medovate has reached an exclusive deal with Vygon Group to distribute SAFIRA (Safer Injection for Regional Anaesthesia). The distribution will cover 60 countries, beginning with a phased launch in Europe at the end of this year, with further global markets set to follow later.

SAFIRA was developed alongside NHS clinicians and makes Peripheral Nerve Blockade a procedure that can be managed by one person, with the anaesthetist fully in control of the injection.

In addition to ease of use, SAFIRA prevents the injection of anaesthetic at high pressures, meaning that the risk of nerve damage is reduced. It is also thought that the system could generate significant time and cost savings.

Medovate Managing Director Stuart Thompson said: “This agreement with Vygon marks a significant milestone in the launch of SAFIRA across Europe, the US and a number of other markets.”

“This will help establish Medovate on the world stage as a recognised medical device developer and manufacturer. In addition, it raises the international profile of the UK NHS and its clinicians, who are key stakeholders in Medovate and inventors of the SAFIRA innovation.”

John Kerridge, VP Anaesthesia and Emergency Business Unit, Vygon, added: “This is a very exciting partnership for Vygon. The SAFIRA technology, in terms of its impact on patient safety and clinical end-user efficiency, is in-line with our overall objective of patient/practitioner-based healthcare solutions.”

“The fact that in the very near future the SAFIRA technology will be available in NRFit format further supports this objective. It will enable us to offer a complete NRFit solution for those markets that demand it.”

Contact us


Tel: +44 (0)1424 777745

Fax: +44 (0)1424 777746



Kirkham Young Ltd.
The Old Court House
North Trade Road
East Sussex
TN33 0EX